Harpoon Therapeutics Launches Immuno-Oncology Pipeline with Compelling Data from Lead Programs at the 2018 American Association for Cancer Research (AACR) Annual Meeting Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and...
Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform Financing round led by Nextech Invest. Proceeds to advance lead oncology programs into the clinic and broaden early-stage pipeline NEW HAVEN, CT, April 4, 2018 – Arvinas LLC, a...
Recent Comments